KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1877184 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.7%
TTM net income YoY-25.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.9%
Operating margin-134.5%
Net margin-140.4%
FCF margin-115.0%
EBITDA margin-125.7%
Returns
ROE-73.7%
ROA-48.8%
ROIC (approx.)-90.4%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.33x
Current ratio4.69x
Interest coverage-18.98x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue32.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-30 | FY20252025-04-30 | FY20242024-04-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | $95.13M | $59.81M | $27.81M |
| Cost of revenue | $46.26M | $35.60M | $27.45M |
| Gross profit | $48.86M | $24.21M | $362,000 |
| R&D expense | $19.48M | $15.65M | $15.49M |
| SG&A expense | $164.12M | $114.94M | $69.94M |
| Operating income | -$134.74M | -$106.38M | -$85.06M |
| Interest expense | $7.55M | $7.73M | $6.23M |
| Pretax income | -$131.32M | -$113.68M | -$94.10M |
| Income tax | $294,000 | $135,000 | $24,000 |
| Net income | -$131.61M | -$113.81M | -$94.12M |
| EBITDA | -$126.03M | -$98.41M | -$73.50M |
| EPS (basic) | -2.43 | -5.13 | -5.07 |
| EPS (diluted) | -2.43 | -5.13 | -5.07 |
| Weighted avg. shares (diluted) | 54.18M | 24.58M | 19.89M |
| Balance sheet | |||
| Cash & equivalents | $99.71M | $237.93M | $8.58M |
| Short-term investments | $96.72M | — | — |
| Receivables | $14.54M | $8.08M | $2.00M |
| Current assets | $222.36M | $255.33M | $14.91M |
| PP&E, net | $59.09M | $34.83M | $26.11M |
| Total assets | $358.46M | $295.74M | $45.95M |
| Current liabilities | $50.37M | $37.98M | $32.97M |
| Long-term debt | $42.65M | $41.10M | $42.54M |
| Total debt | $42.65M | $41.10M | $42.54M |
| Total liabilities | $98.81M | $90.34M | $78.22M |
| Shareholders' equity | $259.66M | $205.41M | -$209.38M |
| Net debt | -$57.06M | -$196.83M | $33.95M |
| Shares outstanding | 58.38M | 51.35M | 105,808 |
| Cash flow statement | |||
| Operating cash flow | -$81.70M | -$77.61M | -$72.23M |
| Capital expenditure | $34.89M | $22.94M | $12.23M |
| Free cash flow | -$116.59M | -$100.54M | -$84.46M |
| Investing cash flow | -$203.28M | -$23.31M | -$12.23M |
| Financing cash flow | $147.09M | $330.26M | $77.72M |
| Depreciation & amortization | $8.71M | $7.97M | $11.56M |
| Stock-based compensation | $33.64M | $24.27M | $1.49M |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.